Charles has been working for over 30 years in healthcare and pharmaceutical research and development working for some of top pharmaceutical companies including SmithKline Beecham, GlaxoSmithKline, Wyeth, Pfizer and AstraZeneca.

During that time he held a number of roles in a wide range of activities including strategy definition and implementation, management, research, operations, reengineering, organization development, business redesign, portfolio management and chief of staff activities. He has been involved in major mergers and acquisitions within the pharmaceutical industry and major change efforts in R&D.

He has developed and demonstrated leadership and project management skills, conceptual, system and analytical thinking, consulting and coaching skills to delivery added value to customers. He has been involved in the governance committees and key decision-making bodies. In addition, he has worked in support departments, such as Finance and Business Strategy, IT and Human Resources.

He has Master of Science (Honors) and Master of Philosophy degrees in Organizational Dynamics from the University of Pennsylvania. He has extensive knowledge of how organizations work, particularly the interfaces between groups and within collaborations.

Charles has a passion for changing organisations and helping leaders to maximize their productivity. He brings a broad range of insights into what works well and what does not work so well, along with knowledge and experience of working in large organisations and collaborations. In the coaching space, Charles brings experience in leadership, managing change and uncertainty. His focus for consulting is working with leaders to maximize collaborations between organizations of different cultures and sizes (e.g., academia, large companies and start-ups).

Finally, Charles is passionate about sharing his learning and experience through teaching and mentoring. He has given guest lectures at Georgetown University and Penn State University, focused on strategic leadership and managing the business of science.